Since the high expression of fibronectin is a marker of EMT and is associated with high-risk breast cancer, molecular MRI with CREKA-Tris(Gd-DOTA)3 has the potential to non-invasively grade and differentiate the aggressiveness of small breast cancer and to assess tumour heterogeneity, which forms a major challenge in the clinical management of breast cancer. The gene discussed is FN1; the disease is breast carcinoma.